Invention Grant
- Patent Title: Anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with P75
-
Application No.: US14664251Application Date: 2015-03-20
-
Publication No.: US09718882B2Publication Date: 2017-08-01
- Inventor: John A. Latham , Ethan W. Ojala , Jeffrey T. L. Smith , Benjamin H. Dutzar , Leon F. Garcia-Martinez
- Applicant: ALDERBIO HOLDINGS LLC
- Applicant Address: US NV Las Vegas
- Assignee: ALDERBIO HOLDINGS LLC
- Current Assignee: ALDERBIO HOLDINGS LLC
- Current Assignee Address: US NV Las Vegas
- Agency: LeClairRyan, A Professional Corporation
- Agent Robin L. Teskin
- Main IPC: A61K39/395
- IPC: A61K39/395 ; C07K16/28 ; C07K16/22 ; A61K45/06 ; A61K31/713 ; A61K39/00

Abstract:
This invention pertains to NGF antagonists including antibodies and antibody fragments thereof having binding specificity to human Nerve Growth Factor (“NGF”), and methods of treating pain. Methods of treating pain or eliciting an analgesic effect in an individual comprising administering an effective amount of an NGF antagonist inhibits the association of NGF with TrkA without inhibiting the association of NGF with p75. The methods may further comprise administering an effective amount of a second anti-human NGF antibody or fragment thereof which inhibits the association of NGF with p75, that may further also inhibit the association of NGF with TrkA.
Public/Granted literature
Information query